[
  {
    "ts": null,
    "headline": "Will Offering the First FDA-Cleared Alzheimer’s Blood Test Reshape Labcorp’s (LH) Long-Term Narrative?",
    "summary": "Labcorp announced it will begin offering the Elecsys pTau181 blood test nationwide by early 2026, making available the only FDA-cleared blood test in the U.S. to aid in the initial assessment for Alzheimer’s disease and cognitive decline in primary-care settings. This marks a significant step forward in expanding access to less invasive neurological diagnostics, helping streamline the testing process for an estimated 7.2 million Americans living with Alzheimer’s disease. We’ll now explore...",
    "url": "https://finnhub.io/api/news?id=4bcf930fd3fa9be9fe011ca0643932e9e4ab8448b4ad4ed052ea321b9e14260d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761225312,
      "headline": "Will Offering the First FDA-Cleared Alzheimer’s Blood Test Reshape Labcorp’s (LH) Long-Term Narrative?",
      "id": 137218124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp announced it will begin offering the Elecsys pTau181 blood test nationwide by early 2026, making available the only FDA-cleared blood test in the U.S. to aid in the initial assessment for Alzheimer’s disease and cognitive decline in primary-care settings. This marks a significant step forward in expanding access to less invasive neurological diagnostics, helping streamline the testing process for an estimated 7.2 million Americans living with Alzheimer’s disease. We’ll now explore...",
      "url": "https://finnhub.io/api/news?id=4bcf930fd3fa9be9fe011ca0643932e9e4ab8448b4ad4ed052ea321b9e14260d"
    }
  },
  {
    "ts": null,
    "headline": "Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings",
    "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics, Labcorp plans to make the test available nationwide by early 2026.",
    "url": "https://finnhub.io/api/news?id=2d3a7530d80316c6d6244e797435f33a649138cf2d83d6730e5b57ef006cd95d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761217200,
      "headline": "Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings",
      "id": 137218125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics, Labcorp plans to make the test available nationwide by early 2026.",
      "url": "https://finnhub.io/api/news?id=2d3a7530d80316c6d6244e797435f33a649138cf2d83d6730e5b57ef006cd95d"
    }
  }
]